Poxel Secures Chinese Patent for Imeglimin Use in Type-2 Diabetes with Renal Issues

Poxel SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announced that China's National Intellectual Property Administration (CNIPA) has granted Poxel patent ZL201980015603.X for Imeglimin, a first-in-class drug targeting mitochondrial dysfunction and marketed in Japan for the treatment of type-2 diabetes.

This new patent protects the use of Imeglimin for type-2 diabetic patients with moderate to severe renal impairment until 2039. The granting of the patent further supports ongoing discussions initiated by Poxel to develop and market Imeglimin in China, following the company's recovery of the rights to this product in Asian countries other than Japan from Sumitomo Pharma. The company also holds 3 additional patents in China covering Imeglimin’s synthesis process.

The prevalence of diabetic patient with chronic kidney disease is high in China, corresponding to around 27% of the country's diabetic population, or nearly 32 million patients. Diabetes is also the leading cause of end-stage renal failure in this country, i.e. requiring dialysis or a kidney transplant.

China is one of Poxel's priority targets for the development and marketing of Imeglimin, where the decisions taken by the Japanese Agency for Pharmaceuticals and Medical Devices, could potentially reduce future regulatory and development times.

“The granting of this patent by the Chinese authorities is in line with our corporate development strategy and represents a partnering opportunity for a biotech company in this strategic territory. Indeed, the medical needs of the Chinese sub-population of type-2 diabetic patients with renal impairment are huge, and this sub-population is in great demand for a safe and efficacious therapeutic solution. We are pursuing our discussions with a view to a strategic partnership for the development and commercialization of Imeglimin, focusing primarily on China, South East Asian countries, as well as other very specific territories enabling us to maximize the approval of Imeglimin already achieved in Japan, thereby reducing the development efforts to be undertaken on a country-by-country basis,” stated Thomas Kuhn, chief executive officer of Poxel.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!